Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 27c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.56, $0.27 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $39.9 million versus the consensus estimate of $46.4 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• General Mills beats estimates as cost savings offset volumes